Share-based Payment Arrangement, Expense of Serina Therapeutics, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Serina Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Serina Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $999,000, a 8.8% decline year-over-year.
  • Serina Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,833,000, a 138% increase year-over-year.
  • Serina Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,595,000, a 10280% increase from 2023.
  • Serina Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25,000, a 97% decline from 2022.
  • Serina Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $760,000, a 24% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Serina Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,833,000 $999,000 -$97,000 -8.8% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $3,930,000 $890,000 +$432,000 +94% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $3,498,000 $956,000 +$903,000 +1704% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $2,595,000 $988,000 +$987,000 +98700% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $1,608,000 $1,096,000 +$1,096,000 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $512,000 $458,000 +$436,000 +1982% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $76,000 $53,000 +$51,000 +2550% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $25,000 $1,000 -$113,000 -99% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $138,000 $0 -$209,000 -100% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $347,000 $22,000 -$176,000 -89% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $523,000 $2,000 -$237,000 -99% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $760,000 $114,000 -$153,000 -57% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q3 2022 $913,000 $209,000 -$63,000 -23% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $976,000 $198,000 -$88,000 -31% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $1,064,000 $239,000 +$61,000 +34% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $1,003,000 $267,000 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2022 2021 FY
Q3 2021 $272,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $286,000 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $178,000 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q4 2018 $184,000 $1,000 01 Oct 2018 31 Dec 2018 10-K/A 31 Mar 2020 2019 FY
Q3 2018 $33,000 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $62,000 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $88,000 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1

Serina Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,595,000 +$2,570,000 +10280% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $25,000 -$735,000 -97% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $760,000 -$243,000 -24% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $1,003,000 +$70,000 +7.5% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2022 2021 FY
2020 $933,000 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2018 $184,000 -$227,000 -55% 01 Jan 2018 31 Dec 2018 10-K/A 31 Mar 2020 2019 FY
2017 $411,000 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.